<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and what allows its progression. Nevertheless, it is accepted that" exact="neurodegeneration" post="is a consequence of several detrimental processes, such as"/>
 <result pre="disease (AD), which is considered the most common form of" exact="dementia" post="characterized by neurodegeneration and cognitive dysfunctions. This review is"/>
 <result pre="is considered the most common form of dementia characterized by" exact="neurodegeneration" post="and cognitive dysfunctions. This review is aimed at collecting"/>
 <result pre="World Health Organization, around 50 million peopleâ€&quot;mostly elderlyâ€&quot;are affected by" exact="dementia" post="with AD representing ca. 60-70% of the cases [1]."/>
 <result pre="dismutase 1 (SOD1), TAR DNA binding protein (TDP-43), fused in" exact="sarcoma" post="(FUS), and repeat dipeptides from noncanonical translation of mutant"/>
 <result pre="72 (C9ORF72) [6]. The other main pathological event leading to" exact="neurodegeneration" post="is oxidative stress. Even if the human brain constitutes"/>
 <result pre="of neurons (lipids, proteins, and nucleic acids) leads invariably to" exact="neurodegeneration" post="[8]. In other words, the constant accumulation of reactive"/>
 <result pre="only in AD but also in other age-related forms of" exact="dementia" post="[27]. Acetylcholinesterase (AChE) rapidly terminates the action of ACh"/>
 <result pre="role played by the aminoquinoline group. The viability of SH-SY5Y" exact="neuroblastoma" post="cells was not affected by concentrations of up to"/>
 <result pre="and the effects on cognition were tested in a scopolamine-induced" exact="amnesia" post="animal model at the maximum dose of 10â€‰mg/kg. Both"/>
 <result pre="a 3C-linker progressed, having an IC50 of 30â€‰Î¼M against the" exact="neuroblastoma" post="cell line and being safe in hepatocytes, with low"/>
 <result pre="activity against AÎ² self-oligomerization. It was then tested in mouse" exact="neuroblastoma" post="N2a-TAU cells at increasing concentrations to assess its effect"/>
 <result pre="development and analysis in additional analysis in animal models of" exact="dementia" post="associated to neurodegenerative conditions. 2.4. ChE Inhibitors and Other"/>
 <result pre="drug NamzaricÂ®) is now used to treat moderate to severe" exact="dementia" post="stages associated with AD [68]. In line with this"/>
 <result pre="= 5.1â€‰nM) was also evaluated in vivo in a dizocilpine-induced" exact="amnesia" post="model, showing a protecting effect in the passive avoidance"/>
 <result pre="cognitive improvement effect in animal models of AD. In scopolamine-induced" exact="amnesia" post="in rodents, it showed spatial memory improvement in the"/>
 <result pre="subtypes. Moreover, both of the structures showed low cytotoxicity in" exact="neuroblastoma" post="cells and were optimal candidates endowed with drug-like properties."/>
 <result pre="and diagnostic tools for an early diagnosis or discovery of" exact="neurodegeneration" post="[142]. Potential targets for peptide-based therapies could be the"/>
 <result pre="oligopeptides have already shown significant effects in animal models of" exact="dementia" post="[144] and an even narrowed set has been progressed"/>
 <result pre="H.An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in" exact="cancer" post="therapyJournal of Medicinal Chemistry201659219575959810.1021/acs.jmedchem.6b0005527416328 56MartireS.MoscaL.dâ€™ErmeM.PARP-1 involvement in neurodegeneration: A"/>
 <result pre="diseases: towards a hypothesis of sigma-1 receptors as amplifiers of" exact="neurodegeneration" post="and neuroprotectionAdvances in Experimental Medicine and Biology201796413315210.1007/978-3-319-50174-1_1028315269 91RyskampD. A.KorbanS.ZhemkovV.KraskovskayaN.BezprozvannyI.Neuronal"/>
</results>
